Track topics on Twitter Track topics that are important to you
VC firm Medicxi invested €9mm ($9.9mm) to launch a new UK pharmaceutical company, Mavalon Therapeutics Ltd., formed to advance Domain Therapeutics SA's small-molecule G protein-coupled receptor (GPCR) pipeline in the area of Parkinson's disease.NEXT ARTICLE
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...